4i0c: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
{{STRUCTURE_4i0c| PDB=4i0c | SCENE= }} | |||
===The structure of the camelid antibody cAbHuL5 in complex with human lysozyme=== | |||
{{ABSTRACT_PUBMED_23919586}} | |||
==Disease== | |||
[[http://www.uniprot.org/uniprot/LYSC_HUMAN LYSC_HUMAN]] Defects in LYZ are a cause of amyloidosis type 8 (AMYL8) [MIM:[http://omim.org/entry/105200 105200]]; also known as systemic non-neuropathic amyloidosis or Ostertag-type amyloidosis. AMYL8 is a hereditary generalized amyloidosis due to deposition of apolipoprotein A1, fibrinogen and lysozyme amyloids. Viscera are particularly affected. There is no involvement of the nervous system. Clinical features include renal amyloidosis resulting in nephrotic syndrome, arterial hypertension, hepatosplenomegaly, cholestasis, petechial skin rash.<ref>PMID:8464497</ref> | |||
==Function== | |||
[[http://www.uniprot.org/uniprot/LYSC_HUMAN LYSC_HUMAN]] Lysozymes have primarily a bacteriolytic function; those in tissues and body fluids are associated with the monocyte-macrophage system and enhance the activity of immunoagents. | |||
==About this Structure== | |||
[[4i0c]] is a 4 chain structure with sequence from [http://en.wikipedia.org/wiki/Camelus_dromedarius Camelus dromedarius] and [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4I0C OCA]. | |||
==Reference== | |||
<ref group="xtra">PMID:023919586</ref><references group="xtra"/><references/> | |||
[[Category: Camelus dromedarius]] | |||
[[Category: Homo sapiens]] | |||
[[Category: Lysozyme]] | |||
[[Category: Chan, P H.]] | |||
[[Category: Chirgadze, D Y.]] | |||
[[Category: Christodoulou, J.]] | |||
[[Category: Dobson, C M.]] | |||
[[Category: Dumoulin, M.]] | |||
[[Category: Genst, E De.]] | |||
[[Category: Kumita, J R.]] | |||
[[Category: Matagne, A.]] | |||
[[Category: Menzer, L.]] | |||
[[Category: Muyldermans, S.]] | |||
[[Category: Pardon, E.]] | |||
[[Category: Robinson, C V.]] | |||
[[Category: Wyns, L.]] | |||
[[Category: Alpha-beta protein]] | |||
[[Category: Beta-barrel]] | |||
[[Category: Glycosidase]] | |||
[[Category: Immune recognition]] | |||
[[Category: Immune system-hydrolase complex]] | |||
Revision as of 09:24, 10 October 2013
The structure of the camelid antibody cAbHuL5 in complex with human lysozymeThe structure of the camelid antibody cAbHuL5 in complex with human lysozyme
Template:ABSTRACT PUBMED 23919586
DiseaseDisease
[LYSC_HUMAN] Defects in LYZ are a cause of amyloidosis type 8 (AMYL8) [MIM:105200]; also known as systemic non-neuropathic amyloidosis or Ostertag-type amyloidosis. AMYL8 is a hereditary generalized amyloidosis due to deposition of apolipoprotein A1, fibrinogen and lysozyme amyloids. Viscera are particularly affected. There is no involvement of the nervous system. Clinical features include renal amyloidosis resulting in nephrotic syndrome, arterial hypertension, hepatosplenomegaly, cholestasis, petechial skin rash.[1]
FunctionFunction
[LYSC_HUMAN] Lysozymes have primarily a bacteriolytic function; those in tissues and body fluids are associated with the monocyte-macrophage system and enhance the activity of immunoagents.
About this StructureAbout this Structure
4i0c is a 4 chain structure with sequence from Camelus dromedarius and Homo sapiens. Full crystallographic information is available from OCA.
ReferenceReference
- ↑ De Genst E, Chan PH, Pardon E, Hsu ST, Kumita JR, Christodoulou J, Menzer L, Chirgadze DY, Robinson CV, Muyldermans S, Matagne A, Wyns L, Dobson CM, Dumoulin M. A Nanobody Binding to Non-Amyloidogenic Regions of the Protein Human Lysozyme Enhances Partial Unfolding but Inhibits Amyloid Fibril Formation. J Phys Chem B. 2013 Sep 24. PMID:23919586 doi:http://dx.doi.org/10.1021/jp403425z
- ↑ Pepys MB, Hawkins PN, Booth DR, Vigushin DM, Tennent GA, Soutar AK, Totty N, Nguyen O, Blake CC, Terry CJ, et al.. Human lysozyme gene mutations cause hereditary systemic amyloidosis. Nature. 1993 Apr 8;362(6420):553-7. PMID:8464497 doi:http://dx.doi.org/10.1038/362553a0